Henan Dongtai Pharmaceutical Co., Ltd. was founded in 2002. It is a comprehensive and modern GMP pharmaceutical enterprise integrating scientific research, production and sales. Since its establishment, it has taken the responsibility of revitalizing China pharmaceutical industry and striving to become an excellent pharmaceutical enterprise. After nearly 20 years of continuous innovation and development, it has gradually grown into a leader in the R & D, production and sales of APIs and pharmaceutical intermediates Enterprise.
The company has been recognized as a national high-tech enterprise, one of the top 100 enterprises in Henan Province, chiral drug Engineering Technology Center, export base for foreign exchange, postdoctoral research and development base, fifty top enterprises and excellent private enterprises in Anyang City, ten trustworthy enterprises and ten top enterprises in Tangyin county, The new technology application project of diclofenac sodium won the second prize of national science and Technology Progress Award and the honorary title of "China Quality and integrity enterprise" of China entry exit inspection and Quarantine Association for three consecutive years.
The company has a number of independent intellectual property core technologies, equipped with advanced analysis, detection, small-scale test and pilot test equipment, which are used in the research and development, production of anti-inflammatory, analgesic, anti-virus and other drugs harmful to human health. The annual comprehensive production capacity of diclofenac sodium, diclofenac potassium, rimantadine, acemetacin, aceclofenac, phenol and refined indolones is more than 3000 tons. The company adheres to the concept of "producing good medicine, benefiting the society", strictly follows the guidelines of ichq7 and GMP in China, and passed the on-site certification and inspection of EDQM in May 2015; passed the on-site certification and inspection of FDA in September; passed the official PMDA certification of Japan in November; passed the re certification of EDQM and the certification of Yuanyuan logo in 2017, passed the on-site certification of FDA in 2018, ISO9000 on-site inspection, and quality assurance The quantity management system has been gradually improved. Among them, diclofenac series products have five system certification certificates in the world (European CEP certificate, Japanese GMP certificate, American FDA inspection certificate, ISO certification certificate, Korean GMP certificate) and domestic GMP certificate, and have become an important research and development, production, export base of diclofenac products in the world. More than 70% of the products are exported to Europe, North America, South America, Southeast Asia, Japan, South Korea and other countries Home and region, in the international market enjoys a good reputation.
In 2017, in response to the government instructions to leave the city and enter the park, the company invested 200 million yuan in the new plant area of Tangyin county industrial cluster area to upgrade the product process of diclofenac series product production line and multi-functional comprehensive workshop production line. The plant area covers 130 mu, with more than 300 employees, and the annual revenue will exceed 500 million yuan.
The company always adheres to the market demand as the core, product innovation as the guide, and the combination of production, learning and research. With its outstanding innovation ability, the company strives to achieve human health and social progress, and to build a global pharmaceutical brand enterprise!